Home » Stocks » Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc. (AERI)

Stock Price: $12.40 USD 0.10 (0.81%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $13.01 +0.61 (4.92%) Aug 12, 4:48 PM

Stock Price Chart

Key Info

Market Cap 576.78M
Revenue (ttm) 81.58M
Net Income (ttm) -201.78M
Shares Out 46.51M
EPS (ttm) -4.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $12.40
Previous Close $12.30
Change ($) 0.10
Change (%) 0.81%
Day's Open 12.38
Day's Range 12.03 - 12.66
Day's Volume 597,330
52-Week Range 10.80 - 26.26

More Stats

Market Cap 576.78M
Enterprise Value 549.83M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.51M
Float 42.97M
EPS (basic) -4.41
EPS (diluted) -4.42
FCF / Share -2.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.00M
Short Ratio 13.58
Short % of Float 27.28%
Beta 0.94
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.07
PB Ratio 6.37
Revenue 81.58M
Operating Income -179.76M
Net Income -201.78M
Free Cash Flow -134.54M
Net Cash 26.95M
Net Cash / Share 0.58
Gross Margin 51.84%
Operating Margin -220.36%
Profit Margin -247.40%
FCF Margin -164.93%
ROA -36.28%
ROE -164.34%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$28.73*
(131.69% upside)
Low
14.0
Current: $12.40
High
50.0
Target: 28.73
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue69.8924.18-------
Revenue Growth189.02%--------
Gross Profit65.0623.54-------
Operating Income-187-210-146-96.87-75.09-48.13-31.15-14.98-12.97
Net Income-200-233-145-99.06-74.36-48.13-31.60-15.64-13.42
Shares Outstanding45.4341.6635.3229.1425.7824.094.960.950.93
Earnings Per Share-4.39-5.58-4.11-3.40-2.88-2.00-6.38-16.39-14.50
Operating Cash Flow-150-153-93.21-79.84-55.75-33.73-16.45-14.97-12.00
Capital Expenditures-9.96-31.31-15.97-5.08-3.28-0.18-0.06-0.05-0.05
Free Cash Flow-160-184-109-84.92-59.03-33.91-16.51-15.02-12.05
Cash & Equivalents30920325023413714069.652.9315.07
Total Debt206-124124123123-2.33-
Net Cash / Debt10320312611013.3317.0269.650.5915.07
Assets45328529024815916070.463.2215.46
Liabilities28657.241551431401323.486.243.81
Book Value16722813610518.7828.0466.98-63.92-48.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aerie Pharmaceuticals, Inc.
Country United States
Employees 380
CEO Vicente J. Anido

Stock Information

Ticker Symbol AERI
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - Major
Unique Identifier NASDAQ: AERI
IPO Date October 25, 2013

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.